757 results about "Intestinal microorganisms" patented technology

A method of treating chronic disorders associated with the presence of abnormal microflora or an abnormal distribution of microflora in the gastrointestinal tract involves removing the host's existing enteric microflora and substitution of feces from a disease screener donor or composition comprising microorganism selected from the group consisting of Bacteroides and E. coli.

The present invention relates to characterizing changes in mammalian gastrointestinal microbiota associated with antibiotic treatment and various disease conditions (such as obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, abnormal lipid metabolism, short stature, osteoporosis, and other disorders of bone formation and mineralization, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, or narrow spectrum antibiotics / anti-bacterial agents that are capable of restoring healthy mammalian bacterial gastrointestinal microbiota.

The present invention relates to characterizing changes in mammalian intestinal microbiota associated with associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (HPMC) and related methods for diagnosing, preventing and treating obesity and related conditions such as metabolic syndrome and diabetes mellitus. Therapeutic methods of the invention involve the use of probiotics, and / or prebiotics, and / or narrow spectrum antibiotics / anti-bacterial agents that are capable of restoring healthy mammalian bacterial intestinal microbiota.

The present invention encompasses cultured collections of a gut microbial community, models comprising such cultures, and methods of use thereof.

A halogenated benzamide derivative characterized by greater specificity for viral pathogens and less disruptive to beneficial gut microflora, according to formula (III):in whichR1 is a halogen atom, andR2-R6 are independently hydrogen, hydroxyl, C1-C4 alkyl, —C1-C4 alkoxy, acyloxy, nitro, halogen, —C(O)R7 where R7 is —C1-C4 alkyl, or, aromatic including salts and hydrates of these compounds.

The present invention relates to methods for transferring gastrointestinal microbiota that preserves viability and bioactivity of the microbiota, even if fastidious, anaerobic, and non-culturable organisms are present. Also provided herein are examples of how manipulating the gastrointestinal microbiota and introducing particular taxa can be used to affect host metabolic status related to weight, fat, and obesity.

The present invention relates to synbiotic compositions comprising probiotic bacterial strains and prebiotic substances that, when combined exhibit synergistic behavior. The synergetic compositions will stimulate the indigenous microflora to restore and reconstitute in vivo gut like conditions after antibiotic associated diarrhea (AAD), and / or other gut infections caused by gastrointestinal pathogens, and relapses thereof, as well as the prevention of said disorders.

Disclosed are a novel tactic acid bacterium, Lactobacillus sakei Probio-65, and the use thereof. The L. sakei Probio-65 strain has acid tolerance, bile acid tolerance and antibiotic resistance, inhibits the growth of harmful pathogenic microorganisms in the body and the intestine of animals, and has immunuenhancing activity. In particular, the novel strain inhibits the growth of Staphylocccus aureus, which is known to be a factor aggravating atopic dermatitis. Thus, the novel strain is useful for preventing or treating atopic dermatitis and allergy-related disorders. Also, the novel strain stabilizes intestinal microflors by inhibiting the abnormal proliferation of harmful microorganisms in the intestine. The L. sakei Probio-65 strain or a culture thereof is useful in pharmaceutical, feed, food, and cosmetic compositions.

A method and system for treating non-alcoholic fatty liver disease (NAFLD) involves the modulation of the gut microbial of a person suffering from NAFLD, and in particular the provision of a probiotic therapy configured to reduce liver aminotransferases, total-cholesterol, TNF-α and to improve insulin resistance in NAFLD patients.

A halogenated benzamide derivative characterized by greater specificity for viral pathogens and less disruptive to beneficial gut microflora, according to formula (III): in which R1 is a halogen atom, and R2-R6 are independently hydrogen, hydroxyl, C1-C4 alkyl, —C1-C4 alkoxy, acyloxy, nitro, halogen, —C(O)R7 where R7 is —C1-C4 alkyl, or, aromatic including salts and hydrates of these compounds and where at least two of R2-R6 are not hydrogen and where at least one of R2-R6 are hydroxy or acyloxy.

The invention provides a Bacillus coagulans HEW-B379 with a probiotic effect. The above strain is named as HEW-B379, and the preservation number of the strain is CGMCC No.12553. The Bacillus coagulans HEW-B379 has a substantial probiotic property, and can effectively inhibit growth breeding of enteropathogenic Escherichia coli, Staphylococcus aureus, Salmonella typhi, salmonella, Shigella, Proteus species, Shewanella putrefaciens and Pseudomonas aeruginosa. The Bacillus coagulans HEW-B379 has strong stress resistance, can resist high temperature and simulated gastric juice and simulate bile salt environment, can keep the survival rate of 99-100%, and can effectively adjust microbial balance of animal intestinal tracts, inhibit growth of harmful microbes, promote nutrition absorption of animals, improve the conversion rate of a feed and improve the productivity of the animals.

The invention provides a microbial marker of colorectal cancer and application of the marker. The microbial marker comprises Faecalibacterium, Streptococcus and Fusobacterium. The microbial marker ofcolorectal cancer has high precision of predicting the risk of colorectal cancer and high sensitivity, only the abundance of the microbial marker of colorectal cancer needs to be obtained, a risk early warning is given out through model calculation, and the possibility of getting colorectal cancer is evaluated. The microbial marker can be used for preventing colorectal cancer, warning a subject and giving the subject a prompt about whether it is necessary to further conduct diagnosis confirmation or not, and is also conductive for individuals to improve the intestinal microbial environment byadjusting diet or medical treatment, so that the risk of getting colorectal cancer is reduced for the individuals.

The invention discloses health-care fodder for freshwater fish. The health-care fodder is mainly prepared by raw materials in percentage by weight as follows: 14%-35% of soybean meal, 1%-5% of fish meal, 15%-45% of miscellaneous meal, 5%-10% of corn distiller dried grains with solubles, 20%-35% of wheat meal, 2%-5% of fish oil and 1.0%-1.4% of a health-care additive, wherein the health-care additive is a mixture of vitamin, mineral, immunity polyhexose, probiotics and a complex enzyme preparation agent. According to nutritional requirements of freshwater fish, plant protein is taken as a main protein source, and the biological value of fodder protein is increased by adjusting balance of amino acid; and simultaneously, the immunity polyhexose, the probiotics, the complex enzyme preparation agent and the like are added, so that the utilization rate of the fodder is increased, antinutritional factors are passivated, enteric microflorae of the freshwater fish are adjusted, the immunity of the freshwater fish is enhanced, contents of hazardous substances in excrement are reduced, water pollution caused by the excrement and undigested fodder in the excrement is reduced, the freshwater fish can healthily grow, and economic benefits for culturing the freshwater fish are increased.

The use of Bifidobacterium lactis CNCM 1-3446 in the manufacture of a medicament or therapeutic nutritional composition for promoting the development of an early bifidogenic intestinal microbiota in infants delivered by caesarean section is disclosed.

This invention relates to the use of an oligosaccharide selected from the group consisting of lacto-N-tetraose, lacto-N-neotetraose, lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose, para-lacto-N-neohexaose, lacto-N-octaose, lacto-N-neooctaose, iso-lacto-N-octaose, para-lacto-N-octaose and lacto-N-decaose in the manufacture of a medicament for infants or a therapeutic nutritional composition for infants for modulating immune responses in a neonatal infant. The invention extends to the use of such an oligosaccharide for modulating the immune system of a neonatal infant to promote the development in the first few weeks of the life of the infant of a beneficial intestinal microbiota comparable with that found in breast fed infants and for reducing the risk of subsequent development of allergy in the infant.

The invention takes protein and a reducing oligosaccharide Maillard product as microcapsule wall materials and applies the protein and the reducing oligosaccharide Maillard product to the production of probiotic microcapsules. A wall material solution is prepared by reaction of following components: the whey protein and isomaltooligosacharide are mixed according to the mass ratio ranging from (1:1) to (10:1) to form a solution, heating treatment is carried out at a constant temperature of 85-95 DEG C for 2-4 hours, Maillard reaction is carried out to generate grafts with different contents, which are used as a wall material solution. The concentrated probiotics are used as a core material, and an endogenesis emulsification gel method and a spraying and drying method are used for producing the probiotic microcapsules. The microcapsule wall materials comprise the milk-based protein and the prebiotics, have nutritional and functional properties and have a wide application range. A Maillard product is used as a wall material structure and is dense, so that the protection capability is enhanced; the fixed point releasing capability is enhanced in the presence of intestinal canal enzymes and intestinal canal microorganisms; and after the releasing, the microcapsule wall materials can provide nutrients for the probiotics. The prepared microcapsules are used as function factors, have a good market prospect and can be used for medicine, food and feed industries.

The use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition for promoting the development of an early bifidogenic intestinal microbiota in infants without siblings.

The invention discloses lactobacillus plantarum L01 which is assigned the accession number CCTCC No.M2014568, and also provides an application of the lactobacillus plantarum L01 in degradation of cholesterol and preparation of a fermented dairy product capable of degrading the cholesterol. The invention has following advantageous effects: the lactobacillus plantarum L01, which is obtained through separation and screening from traditional pickled vegetables, is sourced from traditional foods so that the lactobacillus plantarum L01 is excellent in safety and meanwhile is excellent in acid resistance, cholate resistance and cell adhesion and has a certain effect of maintaining enteric microorganism colony balance. The lactobacillus plantarum L01 can be used for preparing the fermented dairy product, is strong in cholesterol degrading function, can effectively reduce serum cholesterol and can enhance body immunity.

The invention discloses a mental disorder related intestinal tract microbial marker and application thereof. The intestinal tract microbial marker refers to one or more combinations of intestinal tract microbial florae of Prevotella and Bacteroides. The invention further discloses application of the mental disorder related intestinal tract microbial marker in preparing reagents for diagnosing mental disorders and methods for screening food, probiotics or drugs capable of intervening with mental disorders. Particularly, the methods include comparing proportion of microbial florae of Prevotella to microbial florae of Bacteroides before and after treatment or interference of the food, probiotics or drugs and / or comparing relative quantity of microbial florae of Prevotella and microbial florae of Bacteroides in feces specimens.

The invention relates to a compound acidulant which is particularly added into feed of pigs and fowls and belongs to the field of feed additive. The compound acidulant is prepared by the following steps: crushing and sifting anhydrous citric acid, fumaric acid and malic acid powder; placing white carbon black into a mixer primarily, spraying the white carbon black into the mixer by a lactic acid pump to lead the white carbon black to cover all lactic acid; adding the anhydrous citric acid, the fumaric acid, the malic acid and silica into the mixer for mixing later; at last, adding bacillus subtilis and xylo-oligosaccharide into the mixer to be mixed into the finished product. The compound acidulant contains organic acid instead of inorganic acid, and the organic acid can slow the releasing speed of the acidulant so as to enable the acidulant to better exert the function; the compound acidulant has lactic acid taste and good palatability so as to improve the utilization ratio of the feed; compared with the inorganic acidulant, the lactic acid type acidulant has more remarkable effect of lactic acidulant, can better improve the intestinal microflora because of containing beneficial bacterium stimulator, and has remarkable diarrhea-preventing effect, thereby being an ideal digestant of animals.

This invention relates to the use of hydroxybutyrate and poly hydroxybutyrate as components of animal feed or feed additives, as well as to compositions, feed additives and feed containing them. The inventors surprisingly found that hydroxybutyrate and poly-hydroxybutyrate, preferably 3-hydroxybutyrate and poly-3-hydroxybutyrate, have a great potential for use in animal feed for modulation of the gut flora. More precisely, it has been found that poly-3-hydroxybutyrate or a microbial strain capable for producing poly-3-hydroxybutyrate can be used as a potential growth promoter or gut flora modulator by releasing SCFA, preferably 3-hydroxy butyric acid, in the gut micro flora. Further, the inventors found that 3-hydroxybutyrate and poly-3-hydroxybutyrate have a great potential for suppressing or inhibiting pathogenic bacteria in the gastro intestinal tract, e.g. have a antimicrobial activity against strains of Vibrio, E. coli and Salmonella.

The invention relates to the field of biological detection, in particular to a detection and analysis method and system for intestinal microbial florae. The detection and analysis method for the intestinal microbial florae comprises the steps as follows: acquiring an excrement sample; extracting total DNA of microbial flora genome in the excrement sample and performing PCR amplification on the total DNA; performing bioinformatic analysis based on sequencing data to obtain an analysis result; comparing the analysis result with a crowd intestinal microbial flora database to obtain an intestinalmicrobial flora state of a subject; and giving an adjustable index and a monitoring index correspondingly on the basis of the intestinal microbial flora state and the basic condition of the subject. Acorresponding intestinal nutrition structure adjustment suggestion is given on the basis of the detection result obtained by the detection and analysis method for the intestinal microbial florae, andthe internal health index of the subject is increased.

The invention relates to a Microorganisms or / and biological enzyme extracting method for plant anthocyanin, belonging to the technical field of biological engineering. The method comprises the following steps of: classifying plants containing anthocyanin for smashing, adsorbing water, freezing the plants, heating the plants for thawing, pressing the plants, filtering for making juice, cracking and degrading the anthocyanin by the microorganisms or / and the biological enzyme cracking anthocyanin glycosidic bond, utilizing an anion active agent for precipitation reaction, degrading the precipitate by the microorganisms, and carrying out precipitation separation and evaporation concentration. Cation anthocyanin with the real content of more than 95%, namely color primitive but not the anthocyanin can be obtained by the technology of the invention. The cation anthocyanin made by the invention does not need human intestinal microorganisms for degrading, and is directly adsorbed and utilizedby a human body or directly goes into human blood. The medical care value of the plant anthocyanin is much higher than that of the anthocyanin.

Methods and compositions are disclosed for the dietary modulation of the immune system and gut microbial response in animals. Applicant has identified that oral administration of a supplemental spray dried plasma purified from animal serum can modulate serum IgG levels for treatment in such things as diminished immune capacity, intestinal microbial balance, autoimmune disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including humans.

The invention relates to the field of feed, in particular to a compound premix feed of 1% green laying hens in laying period. The compound premix feed of 1% green laying hens in laying period is formed by uniformly mixing micronutrient substances of trace elements, vitamins, synthetic amino acids and the like, feed additives and powdered grain feed as a carrier, and is characterized by comprising active dry yeast, lactic acid bacteria, bacillus and digestive ferment. In the compound premix feed of 1% green laying hens in laying period, active dry yeast, growing element for poultry containing lactic acid bacteria and bacillus can inhibit propagation of pathogen; in wet mixed feed, active dry yeast and the like can be propagated and fermented, and partial pathogen can be inhibited and killed; and the palatability and digestibility of the feed can be improved in a certain time range. Microzyme, lactic acid bacteria and bacillus enter an alimentary tract for quick propagation, and can inhibit the growth of pathogen such as colon bacillus, salmonella and the like, thereby reducing diseases caused by pathogen, generating the effect similar to antibiotics, eliminating the damage of antibiotics to enteric microorganisms, better balancing intestinal flora, improving the immunizing power of laying hens, and improving the health level of laying hens.

The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.

The invention relates to a liquid forage and the preparation method, which comprises the following components in weight percentage: corn 20 to 60 percent, puffing soybean 15 to 50 percent, whey powder 2 to 15 percent, blood plasma protein 1 to 10 percent, fish meal 2 to 15 percent, treacle 1 to 7 percent, soybean oil 1 to 5 percent , CaHPO4 0.1 to 2 percent, stone powder 0.1 to 1 percent, NaCl 0.1 to 2 percent, choline 0.1 to 1 percent, L-Lys (L- lysine salt) 0.1 to 1 percent, DL-Met (methionine) 0.1 to 1 percent, pre-mixture 1.00 to 4.00 percent, and deflocculant 0.1 to 2 percent. Compared with the dry forage, the invention enhances the food intake of weaned newborn pigs; the invention also increases the feeding speed; the liquid forage can avoid the damages of dry forage to the intestinal wall morphology of weaned newborn pigs; liquid forage is beneficial to the inner environment of the digestive canal of newborn pigs; the enhancement of growing performance of early weaning newborn pigs can also be gained from the increase of ADFI, and simultaneously low pH value is also helpful to the protein digestion in the stomach of newborn pigs. The invention has the advantages of the regulation of the growing performance, the influence on the immunity function, and the balance of intestinal microbiological flora of early isolated weaning newborn pigs to reduce the cultivation cost greatly.